CELCUITY INC (CELC)

US15102K1007 - Common Stock

16.76  -0.9 (-5.1%)

After market: 16.76 0 (0%)

News Image
4 days ago - InvestorPlace

CELC Stock Earnings: Celcuity Beats EPS for Q1 2024

CELC stock results show that Celcuity beat analyst estimates for earnings per share the first quarter of 2024.

News Image
4 days ago - BusinessInsider

CELC Stock Earnings: Celcuity Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Celcuity (NASDAQ:CELC) just reported results for the first quarter of 2024.Celc...

News Image
4 days ago - Celcuity Inc.

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed...

News Image
12 days ago - Celcuity Inc.

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
16 days ago - USA News Group

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

/PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging."...

News Image
16 days ago - USA News Group

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

/CNW/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...

News Image
2 months ago - Celcuity Inc.

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
2 months ago - InvestorPlace

CELC Stock Earnings: Celcuity Beats EPS for Q4 2023

CELC stock results show that Celcuity beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - BusinessInsider

CELC Stock Earnings: Celcuity Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Celcuity (NASDAQ:CELC) just reported results for the fourth quarter of 2023.Cel...

News Image
2 months ago - Celcuity Inc.

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant...

News Image
2 months ago - Celcuity Inc.

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
2 months ago - Celcuity Inc.

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
3 months ago - Celcuity Inc.

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
3 months ago - Seeking Alpha

Stifel starts Celcuity at buy, sees gedatolisib as potential blockbuster (NASDAQ:CELC)

Stifel has initiated coverage of Celcuity (CELC) with a buy rating, stating that the company’s drug gedatolisib has “blockbuster potential.” The investment firm

News Image
3 months ago - Celcuity Inc.

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
6 months ago - Celcuity Inc.

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
6 months ago - Celcuity Inc.

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2023 San Antonio Breast Cancer Symposium (SABCS) is being held virtually and in-person from December 5-9, 2023.

News Image
6 months ago - Celcuity Inc.

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
6 months ago - Celcuity Inc.

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today reported financial results for the third quarter ended September 30, 2023 and provided other recent corporate updates.

News Image
7 months ago - Celcuity Inc.

Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences

MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
7 months ago - Seeking Alpha

Celcuity to raise $50M via private placement (NASDAQ:CELC)

Celcuity (CELC) plans to conduct a private placement offering to raise $50 million, with net proceeds going towards clinical development and corporate...

News Image
8 months ago - InvestorPlace

The 7 Best Short-Squeeze Stocks to Buy Now: September 2023

Explore the potential of the best short-squeeze stocks to buy now as companies attempt to prove pessimistic traders wrong.

News Image
9 months ago - Celcuity Inc.

Celcuity to Host Virtual Science Day for Investors

Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in...

News Image
9 months ago - InvestorPlace

7 Short-Squeeze Stocks That Actually Might Make Sense

Although the concept of short-squeeze stocks is one best left for speculators, these ideas have a touch of rationality behind them.

News Image
9 months ago - Celcuity Inc.

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

News Image
9 months ago - Celcuity Inc.

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. –...

News Image
9 months ago - Celcuity Inc.

Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Phase 3 VIKTORIA-1 clinical trial is now recruiting patients at nearly 200 sites in 20 countriesPresented updated results from Phase 1b study of...

News Image
10 months ago - Celcuity Inc.

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted...